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Abstract 
Eukaryotic initiation factor 5A (eIF5A), the only known cellular protein containing the amino acid 
hypusine, is an essential component of translation elongation. eIF5A2, one of the two isoforms in 
the eIF5A family, is reported to be a novel oncogenic protein in many types of human cancer. Both 
in vitro and in vivo studies showed that eIF5A2 could initiate tumor formation, enhance cancer cell 
growth, and increase cancer cell motility and metastasis by inducing epithelial-mesenchymal 
transition. Accumulatied evidence suggests that eIF5A2 is a useful biomarker in the prediction of 
cancer prognoses and serves as an anticancer molecular target. In this review, we will focus on 
updating current knowledge of the EIF5A2 gene in human cancers. The molecular mechanisms of 
EIF5A2 related to tumorigenesis will also be discussed. 
Key words: Eukaryotic initiation factor 5A2, Cancer, Epithelial-mesenchymal transition, Metasta-
sis. 
Introduction 
Amplification of 3q26.2 is one of the most fre-
quent genetic alternations found in solid tumors. In 
2000, our group isolated a putative oncogene, eukar-
yotic translation initiation factor 5A2 (EIF5A2), from 
3q26.2, using the chromosome microdissection- hy-
brid selection technique [1]. In humans, eIF5A2 and its 
isoform eIF5A1 are the only two eukaryotic proteins 
that contain a unique hypusine residue [2, 3]. Hypu-
sine is a polyamine-derived amino acid that is gener-
ated in eIF5A by a post-translational enzymatic mod-
ification that occurs in two steps. The first step in-
volves polyamine spermidine cleavage and the 
transfer of its 4-aminobutyl group to a specific lysine 
residue of the eIF5A precursor by deoxyhypusine 
synthase (DHS), thus forming a deoxyhypusine resi-
due [4, 5]. Subsequent hydroxylation at carbon 2 of 
the transferred 4-aminobutylmoiety intermediated by 
deoxyhypusine hydroxylase (DOHH) produces the 
hypusine residue, a mature and active form of eIF5A 
[6, 7]. Initially, eIF5A was thought to act in the final 
stage of the initiation phase of protein synthesis by 
promoting the formation of the first peptide bond, 
however, rencent reports have also suggested that 
eIF5A participates in translation elongation [8, 9]. To 
date, two eIF5A isoforms have been identified and 
have been found to share about 80% of their cDNA 
sequences and 94% of their proteins. Both human 
eIF5A1 and eIF5A2 were shown to complement 
growth of eIF5A2 null yeast, indicating similar func-
tions between the two human isoforms in terms of 
eukaryotic cell survival [10, 11]. However, the genes 
encoding eIF5A1 and eIF5A2 are located on different 
chromosomes. The EIF5A gene resides on 17p12-p13, 
a genetically stable chromosome. eIF5A1 protein is 
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ubiquitously expressed in almost all cells and tissues 
and plays crucial roles in translation elongation and 
RNA metabolism [9]. In contrast, eIF5A2 expression is 
tissue and cell-type-specific, and is mainly found in 
testis, brain and several cancer cell lines and tissues 
[10]. Our previous studies showed that 
over-expression of eIF5A2 could initiate tumor for-
mation, promote cancer cell growth and enhance cell 
invasion/metastasis by inducing epitheli-
al-mesenchymal transition (EMT) both in vitro and in 
vivo, suggesting it might have an oncogenic role in 
mammals. In this article, we will focus on 
EIF5A2-related studies that have been published over 
the last ten years, particularly those articles pertaining 
to its modification, sub-cellular location, upstream 
regulation and roles in cancer cell proliferation, inva-
sion/metastasis, prognosis and prospects as a form of 
cancer treatment.  
Protein Modification and Sub-cellular 
Location 
eIF5A2 is a small (approximately 17kDa) uni-
versally conserved acidic protein classified in the eIF 
family. The eIF family represents a group of proteins 
that are involved in the initiation step of the protein 
translation. Each member of the eIF family plays a 
unique role in the initiation process by interacting 
with ribosomal subunits and mRNAs to form an 
elongation competent complex [12]. With robust mo-
lecular genetics and biochemical studies, Saini et al. 
verify that eIF5A promotes translation elongation [9]. 
Different from other eIF members, eIF5A2 and its 
isoform eIF5A1 have a polyamine-derived amino ac-
id, hypusine, in their primary structures. Hypusine 
modification at the lysine-50 by DHS and DOHH is 
mandatory for the maturation of eIF5A2 protein [11]. 
Previous studies have shown that many kinds of cy-
tokines and enzymes can enhance or decrease cell 
growth by regulating hypusine synthesis [13-17]. For 
example, transglutaminases (TGase), calci-
um-dependent enzymes, can catalyze formation of a 
cross-link between eIF5A hypusine residue and di-
methylcasein [13, 15]. However, the impacts of the 
aforementioned cytokines and enzymes on eIF5A2 
warrants further investigation. The amino acid se-
quences of the human eIF5A isoforms are conserved 
in the areas where hypusination takes place. The di-
vergent residues between the human eIF5A1 and 
eIF5A2 are mainly located on the C-terminal domain 
[18], suggesting that different functions between the 
two isoforms may be linked to the C-terminal domain. 
The function of the C-terminal domain of eIF5A1 is 
shown by the finding that the mutation of Ser 149 to 
Pro in yeast eIF5A1 decreases general protein synthe-
sis by 30% and increases mRNA stability [19]. How-
ever the biological effects of eIF5A2 C-terminal region 
remain unclear. As to the structure of eIF5A2, in brief, 
the N-terminal domain is dominated by β-strands and 
the C-terminal domain consists of a three-turn α-helix 
α2 and five strands of β7-β11 [18]. 
 In addition to unique hypusine modification, 
Ishfaq et al. find that both eIF5A isoforms are acety-
lated at lysine-47, and hypusination of K50 can reduce 
acetylation in eIF5A2. Moreover, both HDAC6 and 
SIRT were shown to deacetylate eIF5A2 in SW480 
cells when treated with three HDAC inhibitors, tri-
chostatin A (TSA), nicotinamide (NA), and SCOP402. 
The authors further investigated the impact of 
hypusination and acetylation on the subcellular lo-
calization of eIF5A2 via its expression of Flag-tagged 
eIF5A2 wild type and the mutants in Hela cells. The 
results showed that acetylation induced nuclear ac-
cumulation and hypusination induced cytoplasmice 
localization of eIF5A2 [20, 21]. Additionally, in 1995, 
Hannelore Klier et al. purified and characterized one 
major and three minor isoforms of human eIF5A from 
Hela cells. The main form, which accounts for ap-
proximately 95% of all eIF5A, carries hypusine at po-
sition 50 and is amino-terminally acetylated as de-
termined by amino acid composition analysis and 
electrospray ionization mass spectrometry. In contrast 
to the main form, all three minor isoforms of eIF5A 
are characterized by acetylation of lysine at position 
47. Furthermore, no phosphorylation was found in 
any of the purified human eIF5A isoforms [22]. With 
regards to the cellular location of eIF5A, Lipowsky et 
al. found that exportin 4 (Exp4 or XPO4) mediated the 
nuclear export of eIF5A1 by means of the trimetric 
eIF5A1-Exp4-RanGTP complex, which required 
eIF5A1 hypusine modification [23]. In line with these 
findings, Zender and colleagues identified that ex-
portin 4 (XPO4) was the nuclear export mediator of 
eIF5A2 in that nuclear accumulation of eIF5A1 or 
eIF5A2 was found in XPO4 deficient cells [24]. Taken 
together, this evidence indicates that eIF5A2 is a 
shuttling protein responsible for regulating genes’ 
protein elongation in the cytoplasm (Fig 1.). Until 
now, eIF5A2 was still thought to be a cytoplasm pro-
tein and no studies have shown that it can act as a 
transcriptional factor in the nucleus. 
Upstream Regulation 
The EIF5A2 gene resides on chromosome 3q26, a 
region that is frequently amplified in different human 
malignancies, including pancreatic [25], esophageal 
[26, 27], prostate [28], lung [29, 30], gastric [31, 32], 
ovarian [1, 33], colorectal [10, 34], liver [35], bladder 
[36], breast [37], and nasopharyngeal carcinoma [38] 
(Table 1). However, over-expression of eIF5A2 pro-
tein does not always necessarily mean the amplifica-
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tion of the gene. For instance, in the ovarian cancer 
cell line UACC-1598, which has a high fold amplifica-
tion of the EIF5A2 gene, the level of EIF5A2 mRNA is 
much higher than that of EIF5A, yet the amount of 
eIF5A2 protein is merely comparable to that of eIF5A1 
and no modified eIF5A2 is detectable in most cells 
(even when EIF5A2 mRNA is present) [11]. Using 
semi-quantitative RT-PCR and real-time PCR meth-
ods, we have shown that over-expression of eIF5A2 
occurred in 50/81 (61.7%, P <0.0001, independent 
Student’s t test) of HCCs. However, we did not detect 
a significant copy number change in these HCC sam-
ples when using semi-quantitative genomic PCR [35]. 
In 16 bladder urothelial carcinoma tissue samples, 
amplification of EIF5A2 was not observed even when 
eIF5A2 protein was over-expressed [36]. These results, 
taken together, suggest that other mechanisms, such 
as transcriptional regulation and posttranscriptional 
regulation, might play an important role in eIF5A2 
regulation. Clement et al. found that the efficiency of 
eIF5A2 mRNA translation mainly affected the ex-
pression level of eIF5A2 protein since there was little 
difference in stability between eIF5A1 and eIF5A2 
protein [39]. Furthermore, they observed that the 
open reading frames (ORFs) of the two isoforms were 
expressed almost equally in 293T cells, suggesting 
that the negative elements that inhibit the translation 
of EIF5A2 mRNA reside in the 5’-UTR or 3’-UTR. 
Previous studies also showed that poly (A) tail length 
played a critical role in regulating translation. Since 
the long mRNA containing 3.8-kb 3’-UTR is the major 
form of EIF5A2 mRNAs in most cells, 3’-UTRs of 
EIF5A2 may contribute to its variations in its protein 
expression among different cells [39]. Recently, a large 
body of studies demonstrated that microRNA can 
regulate gene expression at the posttranscriptional 
level by base-pairing with the 3’-untranslated region 
(UTR) of target mRNAs, which leads to translational 
repression or message degradation [40]. We therefore 
speculate that microRNA may take part in the regula-
tion of EIF5A2 gene expression. However, the role of 
non-coding RNA (eg, microRNA, lncRNA) in the 
regulation of eIF5A2 expression is still enigmatic. 
Additionally, upstream signals, such as extracellular 
cytokine, membrane receptor and intracellular factor, 
which regulate the expression of EIF5A2 have not 
been sufficiently studied. 
 
Fig 1. Modification and subcellular location of eIF5A2. After modification by DHS and DOHH, eIF5A2 protein is transformed into a mature and active form. 
Nuclear eIF5A2 in complex with RanGTP and XPO4 mediates the export of mature eIF5A2 like eIF5A1. However, if acetylation at lysine-47 occurs, eIF5A2 
might also be accumulated at the nucleus. Since it is not clear whether the hypusination and acetylation of eIF5A occur in cytoplasm or nuclei, a dotted line 
is applied to suggest the possible occurrence of the two processes in both compartments. 
 
Table 1. Summary of gene amplification and protein expression of EIF5A2 in human cancer.  
Reference Materials  Methods Main high level eIF5A2-related conclusions 
Jenkins et al. [10] 76 kinds of human tissues and cell lines NB  Expression of EIF5A2 is limited to testis and parts of the 
brain 
Guan et al. [1] primary ovarian cancer samples and cell 
lines 
SB, FISH Amplification and over-expression of EIF5A2 in ovarian 
cancer 
Clement et al. [11] human cancer cell lines RT-PCR, WB Amplification of EIF5A2 in ovarian cancer and CRC cell 
lines 
Guan et al. [33] ovarian cancer TMA and cell lines IHC, SB, NB, WB Oncogenic role in the development of ovarian cancer  
Clement et al. [39] normal human cells and cancer cell lines WB, NB The expression of EIF5A2 is cell-specific 
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Xie et al. [45] CRC TMA ,CRC tissues IHC, FISH Associated with CRC metastasis 
Yang et al. [63] ovarian tissues IHC, FISH Predicting outcome of ovarian cancer 
Luo et al. [36] paraffin and fresh bladder tissues IHC, FISH, 
RT-PCR, WB 
Predicting pTa/pT1 UC recurrence and progression 
Lee et al. [47] liver tissues and cell lines IHC, qPCR, WB Associated with prognosis of HCC 
Chen et al. [64] bladder cancer tissues and TMA IHC, FISH, 
RT-PCR  
Predicting outcome of UC 
He et al. [65] NSCLC TMA  IHC, FISH Adverse prognosis marker of stage I NSCLC 
Tang et al. [35] HCC tissue TMA and cell lines IHC, IF, RT-PCR, 
qPCR, WB 
Promoting tumor metastasis in HCC 
Zhu et al. [49] CRC TMA and cell lines IHC, WB, IF Inducing EMT in CRC 
FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; NB, northern blot; RT-PCR, reverse transcription and PCR; SB, southern blot; WB; western blot; IF, 
immunofluorescence; TMA: tissue microarray; UC: urothelial carcinoma; NSCLC, non-small cell lung cancer; HCC, hepatocellular carcinoma; CRC, colorectal cancer. 
 
 
Function 
Cell Proliferation  
Accumulating evidence suggests that protein 
synthesis and its translational factors are involved in 
the regulation of cell proliferation and transformation. 
The IF (initiation factor) family plays a virtual role in 
the process of protein translation, and a growing body 
of evidence, which was excellently summarized by 
Caraglia et al., has shown that over-expression of these 
factors is involved in carcinogenesis, tumor cell pro-
liferation and apoptosis [41]. It has been reported that 
eIF5A protein is essential for the sustained prolifera-
tion of mammalian cells [42]. Other studies have 
demonstrated the strong anti-proliferative effects of 
inhibitors of hypusine synthesis, such as 
N1-guanyl-1,7-diaminoheptane (GC7), a DHS inhibi-
tor [43, 44] in mammalian cells, including various 
lines of human cancer cells. Moreover, IFN-α was 
found to inhibit human oropharyngeal epidermoid 
tumor cell growth by modulating hypusine synthesis, 
a process which might be accomplished through af-
fecting eIF5A protein translation [14]. Such findings 
indicate that eIF5A is intimately involved in cell pro-
liferation and may therefore contribute to malignant 
cell transformation. In agreement with these observa-
tions, our previous studies have shown that 
over-expression of eIF5A2 in NIH3T3 cells causes cell 
transformation and that EIF5A2 stably transfected 
LO2 cells (immortalized human liver cell line) dis-
played increased colony formation in soft agar and 
xenograph formation in nude mice. Similarly, the re-
duction of EIF5A2 in UACC-1598 inhibits cell growth; 
and the oncogenic ability of EIF5A2 can also be 
blocked by eIF5A2 silencing [1, 33, 39, 45]. In colorec-
tal cancer, over-expression of eIF5A2 was significantly 
associated with the tumor cell proliferation rate de-
tected by Ki-67 staining on tissue slices. Other groups 
demonstrated that eIF5A2 is required for proliferation 
of XPO4-deficient tumor cells and promotes hepato-
cellular carcinoma (HCC) in mice [24]. These results 
revealed the oncogenic role of eIF5A2 in the control of 
cancer cell proliferation, but the underling mechanism 
has not been elaborated upon. Perhaps in a role simi-
lar to that of eIF5A1, high levels of eIF5A2 protein 
may also enhance oncogenic translation. 
Cancer Invasion/Metastasis 
Metastasis is one of the main causes of mortality 
in the vast majority of solid tumors. Ramaswamy et al. 
found that 17 genes were associated with cancer me-
tastasis by comparing the gene expression profiles of 
metastatic adenocarcinomas and unmatched primary 
adenocarcinomas in several types of human tumors. 
One of the 17 genes in the metastasis signature is de-
oxyhypusine synthase (DHPS), which is required for 
the hypusination of eIF5A2 [46]. In addition, a previ-
ous study showed that over-expression of eIF5A2 was 
significantly associated with lymphovascular inva-
sion in colorectal carcinoma (CRC), venous infiltration 
in HCC, and a higher risk of lymph node metastasis in 
human gastric adenocarcinomas [45, 47, 48]. These 
results suggest that eIF5A2 may be responsible for the 
metastasis of human malignancies. We further inves-
tigated the role of eIF5A2 in the aggressive processes 
of HCC and CRC both in vitro and in vivo by using 
either loss-of-function or gain-of-function studies. We 
thus identified that eIF5A2 plays a pivotal role in 
promoting HCC cell metastasis by enhancing cell 
motility, promoting invasiveness, regulating the cy-
toskeleton, and activating EMT through Rho/Rac 
GTPases [35]. However, despite a lack of changes in 
Rho-GTPase activity, we also found that eIF5A2 en-
hances CRC cell invasion/metastasis and EMT mainly 
by up-regulating MTA1 expression through promot-
ing c-myc, TIP60 and GCN5 binding with MTA1 
promoter [49] (Fig 2.). These findings indicate that the 
metastasis-regulating mechanism of eIF5A2 may be 
tumor-type specific and is dependent on different 
cellular contexts. Clearly, the precise role of eIF5A2 in 
the regulation of cancer cell invasion and/or metas-
tasis in different human cancers requires further in-
vestigation.  
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Fig 2. Clinical values of eIF5A2 in human cancer. Over-expression of eIF5A2 enhances RhoA/Rac1-GTPase activity in HCC and promotes c-myc, TIP60 and 
GCN5 to bind with MTA1 promoter and then up-regulate MTA1 expression in colon cancer. Both of these pathways can increase tumor cell invasion and 
metastasis by inducing EMT. Furthermore, eIF5A2 over-expression has the ability to transform NIH-3T3 fibroblasts, initiate tumor formation and enhance 
tumor cell growth. Based on its function and clinical data, eIF5A2 might be a pivotal human cancer oncogene. 
 
Other Functions  
To investigate the physiological and pathological 
effect of eIF5A2, Chen et al. have generated transgenic 
mice that over-express eIF5A2. Surprisingly, without 
spontaneous tumor formation, overexpression of 
eIF5A2 enhances the aging process of adult transgenic 
mice, including decreased growth rate and body 
weight, shortened life span, kyphosis, osteoporosis, 
delayed of wound healing and ossification. The au-
thors also observed that eIF5A2 activation repressed 
p19, destabilized p53 and led to accumulation of 
chromosomal instability [50]. Previous studies have 
shown that the fate of oncogene activation is 
cell-specific and context dependent. For instance, 
c-Myc has been reported to enhance cell proliferation 
and malignant transformation in several kinds of 
human cancers since it was first reported by Bishop et 
al. in the 1970s [51-55]. But aberrant expression of 
c-myc can also induce apoptosis [56, 57]. Other stud-
ies have also shown that cellular senescence can be 
triggered by oncogene activation, as well as agents 
that damage DNA or alter chromatin structure [58, 
59]. Future studies to investigate and confirm the 
other biological functions of EIF5A2 are warranted, 
and mice with EIF5A2 deficiency might be a good 
choice for such studies. In yeast, the eIF5A isoforms, 
eIF5A1 and eIF5A2, with 92% identity, are encoded by 
the two eIF5A genes, TIF51A and TIF51B respectively 
[60]. Although these 2 genes are reciprocally regulat-
ed by oxygen availability in yeast, they are function-
ally identical, and expression of either gene is suffi-
cient for supporting yeast growth. Under aerobic 
conditions, only TIF51A is transcriptionally active, 
thus leading to eIF5A1 synthesis. In contrast, as oxy-
gen is depleted and anaerobic conditions are estab-
lished, TIF51B transcription is turned on when 
TIF51A is turned off, thereby ensuring the exclusive 
synthesis of eIF5A2 [61]. In a recent study, Vu et al. 
show that the hydroxylase activity of human DOHH 
is positively related to oxygen availability. In hypoxia, 
eIF5A cannot be fully hypusined [61]. Based on this 
evidence, we can speculate that the sub-cellular loca-
tion of eIF5A2 may partly depend upon the availabil-
ity of oxygen, but how oxygen affects the location 
eIF5A2 in mammals is not yet clear.  
eIF5A2 and Prognosis of Human Cancers 
Over the past ten years, many tissue-based 
studies have evaluated the expression of EIF5A2 
mRNA and its encoded protein in human cancers. The 
majority of these studies demonstrated that eIF5A2 
could be used as a biomarker for predicting progno-
sis. Over-expression of eIF5A2 was found to be cor-
related with a more advanced cancer stage and poor 
prognosis in patients with ovarian cancer [63]. In 
HCC, over-expression of eIF5A2 was reported to be 
associated with tumor features that indicate poor 
prognosis, such as the presence of tumor metastasis 
and venous infiltration [47]. A recent study from our 
group also showed similar results in CRC patients. 
Briefly summarized, a high level of eIF5A2 expression 
was found to be related to both lymph node and dis-
tant metastasis, as well as a more advanced clinical 
stage. In addition, eIF5A2 expression was an inde-
pendent prognostic factor for poor CRC patients sur-
vival [48]. eIF5A2 may also play a role in the progno-
sis of patients with early stage tumors. For instance, a 
study assessing patients with bladder urothelial car-
cinoma showed that the overexpression of eIF5A2 as 
detected by IHC was able to predict the recurrence 
and progression of stage pTa/pT1 tumors [36]. In one 
of our previous studies, we concluded that the 
up-regulated expression of eIF5A2 might play an 
important role in the acquisition of a recurrence phe-
notype in superficial bladder cancer [64]. We reached 
a similar conclusion in one of our studies concerned 
with non-small cell lung cancer, which indicated that 
the overexpression of eIF5A2 was an adverse prog-
nostic biomarker for the survival of stage I non–small 
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cell lung cancer patients [65]. These studies demon-
strate that eIF5A2 is a potential prognostic indicator in 
many solid cancers. However, as a cytoplasmic pro-
tein, eIF5A2 can only be assessed in tissue samples by 
PCR or IHC [66].  
Implications for Therapy 
eIF5A is of considerable interest as a potential 
therapeutic target in many human disorders. eIF5A is 
important in protein translation since disruption of 
the hypusination process by the DHS inhibitor, 
N1-guanyl- 1,7-diaminoheptane (GC7), has been 
shown to inhibit the growth of endothelial cells [67]. 
Moreover, mutants of eIF5A that cannot be 
hypusinated induce apoptosis in numerous cancer 
cell types including colon, cervical, skin, and lung 
cancer [68-70], thus inhibiting the growth of solid 
tumors [3]. eIF5A and syntenin can induce 
p53-dependent apoptosis collaboratively [71], but 
eIF5A has also been shown to initiate apoptosis 
through the mitochondrial pathway via the activation 
of caspases in p53-deficient cells [69]. In addition, the 
clinical drugs ciclopirox and deferiprone could impair 
transcription from HIV-1 promoters and decrease 
HIV-1 gene expression by inhibiting eIF5A hypusina-
tion [72]. Furthermore, eIF5A hypusination inhibition 
was demonstrated to have an anti-tumorigenic effect 
on leukemia cells when cells given either CPX alone 
or in combination with imatinib [73]. Our previous 
study showed that a combined treatment of eIF5A2 
siRNA and GC7, an inhibitor of DHS, on HCC cells 
results in the synergistic inhibition of cell migration 
[35]. It was also shown that IFNα can inhibit tumor 
growth by decreasing hypusine synthesis and induce 
human lung epidermoid tumor cell apoptosis when 
combined with GC7 [14, 16]. Since the function of 
eIF5A is specifically regulated by hypusine modifica-
tion [16, 41], a combination therapy of pharmacologi-
cal agents which aim to inhibit the process of hypu-
sine modification, such as GC7, ciclopirox (CPX) and 
cytokines, seems to be a reasonable recommendation 
for the future preclinical or clinic trials.  
Conclusion and Perspectives 
In summary, basic studies and clinical evidence 
show that eIF5A2 is a bona fide oncogene that may also 
be an important biomarker for the prognosis of many 
kinds of human tumors. In addition, antisense DNA 
against EIF5A2 or EIF5A2 specific siRNA effectively 
inhibits tumor cell growth and reduces tumor cells’ 
ability to migrate. Therefore, eIF5A2 holds the poten-
tial to become a novel target for anticancer therapy. 
However, the underlying molecular mechanisms that 
regulate eIF5A2 expression remain enigmatic, such as 
how does non-coding RNA regulates the UTR of 
EIF5A2 and how its promoter is epigenetically modi-
fied. With regard to the downstream pathway, the 
exact mechanism of eIF5A2 in modulating and regu-
lating its target as well as whether or not it can act as a 
transcriptional factor has not been elucidated. To 
further investigate the physiological and pathological 
role of eIF5A2 in mammals, eIF5A2 knockout mice 
may be needed.  
Abbreviations 
eIF5A2: eukaryotic initiation factor 5A2; EMT: 
epithelial-mesenchymal transition; DHPS: deoxy-
hypusine synthase; DOHH: deoxyhypusine hydrox-
ylase; cDNA: complementary deoxyribonucleic acid; 
mRNA: message ribonucleic acid; HDAC: his-
tonedeacetylase; SIRT2: sirtuin 2; TSA: trichostatin A; 
NA: nicotinamide; Exp4/XPO4: exportin 4; RT-PCR: 
reverse transcription polymerase chain reaction; 
HCC: hepatocellular carcinoma; ORF: open reading 
frame; UTR: untranslation region; lncRNA: long 
non-coding ribonucleic acid; siRNA: small interfering 
RNA; GC7: N1-guanyl-1,7-diaminoheptane; CRC: 
colorectal carcinoma; TIF: translation initiation factor; 
IHC: immunohistochemistry; HIV: human immuno-
deficiency virus. IFN α, Interferon α; TGase, 
transglutaminases; CPX, ciclopirox; DEF, deferiprone; 
EGF, epidermal growth factor. 
Acknowledgements 
This work was supported by grants from the 
Nature Science Foundation of China (No. 81225018) 
and the PhD Programs Foundation of the Ministry of 
Education of China (No 20110171110078). 
Competing Interests 
The authors have no financial conflicts of interest 
to disclose. 
References 
1.  Guan XY, Sham JS, Tang TC, et al. Isolation of a novel candidate oncogene 
within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res. 
2001; 61:3806-3809. 
2.  Park MH, Nishimura K, Zanelli CF, et al. Functional significance of eIF5A and 
its hypusine modification in eukaryotes. Amino Acids 2010; 38:491-500. 
3.  Caraglia M, Park MH, Wolff EC, et al. eIF5A isoforms and cancer: two brothers 
for two functions?. Amino Acids 2013; 44:103-109. 
4.  Park MH, Wolff EC, Folk JE. Hypusine: its post-translational formation in 
eukaryotic initiation factor 5A and its potential role in cellular regulation. 
Biofactors 1993; 4:95-104. 
5.  Chen KY, Liu AY. Biochemistry and function of hypusine formation on 
eukaryotic initiation factor 5A. Biol Signals 1997; 6:105-109. 
6.  Abbruzzese A. Developmental pattern for deoxyhypusine hydroxylase in rat 
brain. J Neurochem. 1988;50:695-699 
7.  Abbruzzese A, Park MH, Beninati S, et al. Inhibition of deoxyhypusine 
hydroxylase by polyamines and by a deoxyhypusine peptide. Biochim 
Biophys Acta. 1989;997:248-255. 
8.  Caraglia M, Budillon A, Vitale G, et al. Modulation of molecular mechanisms 
involved in protein synthesis machinery as a new tool for the control of cell 
proliferation. Eur. J. Biochem. 2000; 267:3919-3936.  
9.  Saini P, Eyler DE, Green R, et al. Hypusine-containing protein eIF5A promotes 
translation elongation. Nature 2009; 459:118-121. 
10.  Jenkins ZA, Haag PG, Johansson HE. Human eIF5A2 on chromosome 
3q25-q27 is a phylogenetically conserved vertebrate variant of eukaryotic 
Int. J. Biol. Sci. 2013, Vol. 9 
 
http://www.ijbs.com 
1019 
translation initiation factor 5A with tissue-specific expression. Genomics 2001; 
71:101-109. 
11.  Clement PM, Henderson CA, Jenkins ZA, et al. Identification and 
characterization of eukaryotic initiation factor 5A-2. Eur J Biochem. 2003; 
270:4254-4263. 
12.   Jackson RJ, Hellen CU, Pestova TV. The mechanism of eukaryotic translation 
initiation and principles of its regulation. Nat Rev Mol Cell Biol. 2010; 
11:113-127. 
13.  Beninati S, Nicolini L, Jakus J, et al. Identification of a substrate site for 
transglutaminases on the human protein synthesis initiation factor 5A. 
Biochem J. 1995; 305:725-728. 
14.  Caraglia M, Passeggio A, Beninati S, et al. Interferon a2 recombinant and 
epidermal growth factor modulate proliferation and hypusine synthesis in 
human epidermoid cancer KB cells. Biochem J. 1997; 324:737-741. 
15.  Beninati S, Gentile V, Caraglia M, et al. Tissue transglutaminase expression 
a¡ects hypusine metabolism in BALB/c 3T3 cells. FEBS Letters 1998; 437:34-38 
16.  Caraglia M, Marra M, Giuberti G, et al. The eukaryotic initiation factor 5A is 
involved in the regulation of proliferation and apoptosis induced by 
interferon-a and EGF in human cancer cells. J Biochem. 2003;133:757-765. 
17.  Lalande M, Hanauske-Abel HM. A new compound which reversibly arrests T 
lymphocyte cell cycle near the G1/S boundary. Exp Cell Res. 1990; 
188:117-121. 
18.  Tong Y, Park I, Hong BS et al. Crystal structure of human eIF5A1: insight into 
functional similarity of human eIF5A1 and eIF5A2. Proteins 2009; 
75:1040-1045. 
19.  Zuk D, Jacobson A. A single amino acid substitution in yeast eIF-5A results in 
mRNA stabilization. EMBO J. 1998; 17:2914-2925. 
20.  Ishfaq M, Maeta K, Maeda S et al. The role of acetylation in the subcellular 
localization of an oncogenic isoform of translation factor eIF5A. Biosci 
Biotechnol Biochem. 2012; 76:2165-2167. 
21.  Ishfaq M, Maeta K, Maeda S et al. Acetylation regulates subcellular 
localization of eukaryotic translation initiation factor 5A (eIF5A). FEBS Lett. 
2012; 586:3236-3241. 
22.  Klier H, Csonga R, Joao HC et al. Isolation and structural characterization of 
different isoforms of the hypusine-containing protein eIF-5A from HeLa cells. 
Biochemistry 1995; 34:14693-14702. 
23.  Lipowsky G, Bischoff FR, Schwarzmaier P et al. Exportin 4: a mediator of a 
novel nuclear export pathway in higher eukaryotes. EMBO J. 2000; 
19:4362-4371. 
24. Zender L, Xue W, Zuber J et al. An oncogenomics-based in vivo RNAi screen 
identifies tumor suppressors in liver cancer. Cell 2008; 135:852-864. 
25. Griffin CA, Morsberger L, Hawkins AL et al. Molecular cytogenetic 
characterization of pancreas cancer cell lines reveals high complexity 
chromosomal alterations. Cytogenet Genome Res. 2007; 118:148-156. 
26. Yen CC, Chen YJ, Pan CC et al. Copy number changes of target genes in 
chromosome 3q25.3-qter of esophageal squamous cell carcinoma: TP63 is 
amplified in early carcinogenesis but down-regulated as disease progressed. 
World J Gastroenterol. 2005; 11:1267-1272. 
27.  Pack SD, Karkera JD, Zhuang Z et al. Molecular cytogenetic fingerprinting of 
esophageal squamous cell carcinoma by comparative genomic hybridization 
reveals a consistent pattern of chromosomal alterations. Genes Chromosomes 
Cancer 1999; 25:160-168. 
28.  Sattler HP, Lensch R, Rohde V et al. Novel amplification unit at chromosome 
3q25-q27 in human prostate cancer. Prostate 2000; 45:207-215. 
29.  Viegas-Pequignot E, Flury-Herard A, De Cremoux H et al. Recurrent 
chromosome aberrations in human lung squamous cell carcinomas. Cancer 
Genet Cytogenet. 1990; 49:37-49. 
30.  Shen H, Zhu Y, Wu YJ et al. Genomic alterations in lung adenocarcinomas 
detected by multicolor fluorescence in situ hybridization and comparative 
genomic hybridization. Cancer Genet Cytogenet. 2008; 181:100-107. 
31.  Guan XY, Fu SB, Xia JC et al. Recurrent chromosome changes in 62 primary 
gastric carcinomas detected by comparative genomic hybridization. Cancer 
Genet Cytogenet. 2000; 123:27-34. 
32.  Takada H, Imoto I, Tsuda H et al. Screening of DNA copy-number aberrations 
in gastric cancer cell lines by array-based comparative genomic hybridization. 
Cancer Sci. 2005; 96:100-110. 
33.  Guan XY, Fung JM, Ma NF et al. Oncogenic role of eIF-5A2 in the development 
of ovarian cancer. Cancer Res. 2004; 64:4197-4200. 
34.  He QJ, Zeng WF, Sham JS et al. Recurrent genetic alterations in 26 colorectal 
carcinomas and 21 adenomas from Chinese patients. Cancer Genet Cytogenet. 
2003; 144:112-118. 
35.  Tang DJ, Dong SS, Ma NF et al. Overexpression of eukaryotic initiation factor 
5A2 enhances cell motility and promotes tumor metastasis in hepatocellular 
carcinoma. Hepatology 2010; 51:1255-1263. 
36.  Luo JH, Hua WF, Rao HL et al. Overexpression of EIF-5A2 predicts tumor 
recurrence and progression in pTa/pT1 urothelial carcinoma of the bladder. 
Cancer Sci. 2009; 100:896-902. 
37.  Forozan F, Mahlamaki EH, Monni O et al. Comparative genomic 
hybridization analysis of 38 breast cancer cell lines: a basis for interpreting 
complementary DNA microarray data. Cancer Res. 2000; 60:4519-4525. 
38.  Fang Y, Guan X, Guo Y et al. Analysis of genetic alterations in primary 
nasopharyngeal carcinoma by comparative genomic hybridization. Genes 
Chromosomes Cancer 2001; 30:254-260. 
39.  Clement PM, Johansson HE, Wolff EC et al. Differential expression of eIF5A-1 
and eIF5A-2 in human cancer cells. FEBS J. 2006; 273:1102-1114. 
40.  Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 
2004; 116:281-297. 
41.  Caraglia M, Marra M, Giuberti G, et al. The role of eukaryotic initiation factor 
5A in the control of cell proliferation and apoptosis. Amino Acids. 2001; 
20:91-104. 
42.  Wolff EC, Kang KR, Kim YS et al. Posttranslational synthesis of hypusine: 
evolutionary progression and specificity of the hypusine modification. Amino 
Acids 2007; 33:341-350. 
43.  Nishimura K, Murozumi K, Shirahata A et al. Independent roles of eIF5A and 
polyamines in cell proliferation. Biochem J. 2005; 385:779-785. 
44.  Jasiulionis MG, Luchessi AD, Moreira AG et al. Inhibition of eukaryotic 
translation initiation factor 5A (eIF5A) hypusination impairs melanoma 
growth. Cell Biochem Funct. 2007; 25:109-114. 
45.  Xie D, Ma NF, Pan ZZ et al. Overexpression of EIF-5A2 is associated with 
metastasis of human colorectal carcinoma. Hum Pathol. 2008; 39:80-86. 
46.  Ramaswamy S, Ross KN, Lander ES et al. A molecular signature of metastasis 
in primary solid tumors. Nat Genet. 2003; 33:49-54. 
47.  Lee NP, Tsang FH, Shek FH et al. Prognostic significance and therapeutic 
potential of eukaryotic translation initiation factor 5A (eIF5A) in 
hepatocellular carcinoma. Int J Cancer 2010; 127:968-976. 
48.  Marchet A, Mocellin S, Belluco C et al. Gene expression profile of primary 
gastric cancer: towards the prediction of lymph node status. Ann Surg Oncol. 
2007; 14:1058-1064. 
49.  Zhu W, Cai MY, Tong ZT et al. Overexpression of EIF5A2 promotes colorectal 
carcinoma cell aggressiveness by upregulating MTA1 through C-myc to 
induce epithelial-mesenchymaltransition. Gut 2012; 61:562-575 
50.  Chen M, Huang JD, Deng HK et al. Overexpression of eIF-5A2 in mice causes 
accelerated organismal aging by increasing chromosome instability. BMC 
Cancer 2011; 11:199. 
51.  Amati B, Alevizopoulos K, Vlach J. Myc and the cell cycle. Front Biosci. 1998; 
3:250-268. 
52.  Bishop JM. Retroviruses and cancer genes. Adv Cancer Res. 1982; 37:1-32. 
53.  Bouchard C, Staller P, Eilers M. Control of cell proliferation by Myc. Trends 
Cell Biol. 1998; 8:202-206. 
54.  Dang CV. c-Myc target genes involved in cell growth, apoptosis, and 
metabolism. Mol Cell Biol. 1999; 19:1-11. 
55.  Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic 
disease. Oncogene 1999; 18:3004-3016. 
56.  Evan GI, Wyllie AH, Gilbert CS et al. Induction of apoptosis in fibroblasts by 
c-myc protein. Cell 1992; 69:119-128. 
57.  Shi Y, Glynn JM, Guilbert LJ et al. Role for c-myc in activation-induced 
apoptotic cell death in T cell hybridomas. Science 1992; 257:212-214. 
58.  Campisi J. Aging and cancer: the double-edged sword of replicative 
senescence. J Am Geriatr Soc. 1997; 45:482-488. 
59.  Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen 
to good cells. Nat Rev Mol Cell Biol. 2007; 8:729-740. 
60.  Kang HA, Schwelberger HG, Hershey JW. The two genes encoding protein 
synthesis initiation factor eIF-5A in Saccharomyces cerevisiae are members of 
a duplicated gene cluster. Mol Gen Genet. 1992; 233:487-490. 
61.  Schwelberger HG, Kang HA, Hershey JW. Translation initiation factor eIF-5A 
expressed from either of two yeast genes or from human cDNA. Functional 
identity under aerobic and anaerobic conditions. J Biol Chem. 1993; 
268:14018-14025. 
62.  Vu VV, Emerson JP, Martinho M et al. Human deoxyhypusine hydroxylase, an 
enzyme involved in regulating cell growth, activates O2 with a nonheme 
diiron center. Proc Natl Acad Sci. 2009; 106:14814-14819. 
63.  Yang GF, Xie D, Liu JH et al. Expression and amplification of eIF-5A2 in 
human epithelial ovarian tumors and overexpression of EIF-5A2 is a new 
independent predictor of outcome in patients with ovarian carcinoma. 
Gynecol Oncol. 2009; 112:314-318. 
64.  Chen W, Luo JH, Hua WF et al. Overexpression of EIF-5A2 is an independent 
predictor of outcome in patients of urothelial carcinoma of the bladder treated 
with radical cystectomy. Cancer Epidemiol Biomarkers Prev. 2009; 18:400-408. 
65.  He LR, Zhao HY, Li BK et al. Overexpression of eIF5A-2 is an adverse 
prognostic marker of survival in stage I non-small cell lung cancer patients. Int 
J Cancer 2011; 129:143-150. 
66.  Shek FH, Fatima S, Lee NP. Implications of the Use of Eukaryotic Translation 
Initiation Factor 5A (eIF5A) for Prognosis and Treatment of Hepatocellular 
Carcinoma. Int J Hepatol. 2012; 2012:760-928. 
67.  Lee Y, Kim HK, Park HE et al. Effect of N1-guanyl-1,7-diaminoheptane, an 
inhibitor of deoxyhypusine synthase, on endothelial cell growth, 
differentiation and apoptosis. Mol Cell Biochem. 2002; 237:69-76. 
68.  Taylor CA, Sun Z, Cliche DO et al. Eukaryotic translation initiation factor 5A 
induces apoptosis in colon cancer cells and associates with the nucleus in 
response to tumour necrosis factor alpha signalling. Exp Cell Res. 2007; 
313:437-449. 
69.  Sun Z, Cheng Z, Taylor CA et al. Apoptosis induction by eIF5A1 involves 
activation of the intrinsic mitochondrial pathway. J Cell Physiol. 2010; 
223:798-809. 
70.  Moore CC, Martin EN, Lee G et al. Eukaryotic translation initiation factor 5A 
small interference RNA-liposome complexes reduce inflammation and 
increase survival in murine models of severe sepsis and acute lung injury. J 
Infect Dis. 2008; 198:1407-1414. 
71.  Li AL, Li HY, Jin BF et al. A novel eIF5A complex functions as a regulator of 
p53 and p53-dependent apoptosis. J Biol Chem. 2004; 279:49251-49258. 
Int. J. Biol. Sci. 2013, Vol. 9 
 
http://www.ijbs.com 
1020 
72.  Hoque M, Hanauske-Abel HM, Palumbo P et al. Inhibition of HIV-1 gene 
expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of 
eukaryotic initiation factor 5A. Retrovirology 2009; 6:90. 
73.  Balabanov S, Gontarewicz A, Ziegler P, et al. Hypusination of eukaryotic 
initiation factor 5A (eIF5A):a novel therapeutic target in BCR-ABL-positive 
leukemias identified by a proteomics approach. Blood 2007; 109:1701-1711. 
